Gitasha Chand
Chief Tech/Sci/R&D Officer presso RADIOPHARM THERANOSTICS LIMITED
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Hong-Hoi Ting | M | - |
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 anni |
Thomas Tulip | M | 71 | 3 anni | |
Riccardo Canevari | M | - | 3 anni | |
Ian Turner | M | - | - | |
Levente Meszaros | M | - |
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 2 anni |
Hester Larkin | F | - | 2 anni | |
Henry Ho | M | - |
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 anni |
Paul Hopper | M | 68 | 3 anni | |
Vittorio Puppo | M | - | 2 anni | |
Scot Harper | M | 67 | 3 anni | |
Leila Alland | M | 61 | 2 anni | |
Nathan Jong | M | - | - | |
David Mozley | M | - | - | |
Sherin Al-Safadi | M | - | 1 anni | |
Antje Wegener | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Michael Baker | M | - | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Australia | 14 | 87.50% |
Cina | 3 | 18.75% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Gitasha Chand
- Contatti personali